Remove 2012 Remove Communication Remove Documentation
article thumbnail

International regulation: the importance of quality assurance in drug development

European Pharmaceutical Review

Since the first ADC was approved by the EMA in 2012, they have generated a great deal of interest in the oncology field because of their potential to address many of the challenges of traditional chemotherapy options. Teams must also accept the variety of analytical procedures these regulatory agencies prefer.

article thumbnail

What conditions qualify for disability benefits?

The Checkup by Singlecare

Below, we detail the 14 categories of conditions that qualify for SSA disability in adults and what you may be expected to provide for documentation for each. The SSA also requires persuasive medical documentation from a healthcare provider. (This is not to be confused with Medicare Part A and Part B.)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to take care of your BIPOC patients

The Checkup by Singlecare

continues to impact BIPOC individuals and contribute to documented racial and ethnic disparities in health care. It’s worth considering how you can do so, such as through building trust and open communication. Pain Medicine (2012) Residential Segregation and Disparities in Healthcare Services Utilization.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

7 The additional substantial economic benefits that flow from room-temperature storability have also been thoroughly documented. About the author Dr Bruce Roser MB BS, PhD founded Stablepharma in 2012, to bring to market his important work on vaccine stabilisation. Internet] WHO. cited 2023July]. Available from: [link] WHO.

Vaccines 111
article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

2012: Following the recommendation of the GAO, HRSA began conducting audits of 340B covered entities and later expands audits to drug manufacturers. Instead, they must rely on the government to enforce the pricing provisions of the program. 340B providers expressed significant concern.

article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

While remote communication with HCPs rose in all countries in the same time period, not all remote engagement was the type likely to be described as meaningful – much of the volume was in emails, with WhatsApp, and other remote messaging, also important during the peak infection period.

article thumbnail

Enabling Global Pharma Innovation: Delivering for Patients

ISPE

In addition, this article provides an explanation of the purpose and expected outcomes from the survey, subsequent plans for communicating the results from the survey across ISPE, and development of concrete proposals to address the sources of challenges and barriers to innovation. Published May 2012. 22 June 2023. EMA/321483/2020.

FDA 52